Amgen, Watson will develop follow-on biologics for cancer

12/19/2011 | Wall Street Journal, The

Amgen will team up with Watson Pharmaceuticals to develop and commercialize follow-on versions of several antibody biotech drugs for cancer, excluding Amgen's products. Amgen will be in charge of development, production and initial marketing. Watson will provide as much as $400 million for product development and contribute its commercialization and marketing know-how.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT